SNSE (Sensei Biotherapeutics) Cash And Cash Equivalents : $9.88 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Cash And Cash Equivalents?

Sensei Biotherapeutics's quarterly cash and cash equivalents declined from Sep. 2024 ($19.13 Mil) to Dec. 2024 ($9.99 Mil) but then stayed the same from Dec. 2024 ($9.99 Mil) to Mar. 2025 ($9.88 Mil).

Sensei Biotherapeutics's annual cash and cash equivalents declined from Dec. 2022 ($17.80 Mil) to Dec. 2023 ($13.01 Mil) and declined from Dec. 2023 ($13.01 Mil) to Dec. 2024 ($9.99 Mil).

Sensei Biotherapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Sensei Biotherapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Cash And Cash Equivalents Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

16.60

7.16

17.80

13.01

9.99

Sensei Biotherapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															10.96	11.89	19.13	9.99	9.88

Sensei Biotherapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sensei Biotherapeutics (NAS:SNSE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sensei Biotherapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

407:Germany

Address

1405 Research Boulevard, Suite 125, Rockville, MD, USA, 20850

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Executives

Stephanie Krebs	officer: Chief Business Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi	director, officer: President & CEO	SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer	director, 10 percent owner	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc	10 percent owner, other: See Remarks	228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p.	other: See Explanation of Responses	340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c.	10 percent owner	340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher	officer: Chief Business Officer	66 HAROLD ST, BOSTON MA 02119
William R Ringo	director
Thomas G Ricks	director	H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer	director	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English	director	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850